

**STUDY PROTOCOL**

**Open Access**

# Susceptibility to particle health effects, miRNA and exosomes: rationale and study protocol of the SPHERE study

Valentina Bollati<sup>1\*</sup>, Simona Iodice<sup>1</sup>, Chiara Favero<sup>1</sup>, Laura Angelici<sup>1</sup>, Benedetta Albetti<sup>1</sup>, Raquel Cacace<sup>2</sup>, Laura Cantone<sup>1</sup>, Michele Carugno<sup>1</sup>, Tommaso Cavalleri<sup>1</sup>, Barbara De Giorgio<sup>1</sup>, Laura Dioni<sup>1</sup>, Silvia Fustinoni<sup>1,2</sup>, Mirjam Hoxha<sup>1</sup>, Barbara Marinelli<sup>1</sup>, Valeria Motta<sup>1</sup>, Lorenzo Patrini<sup>4</sup>, Laura Pergoli<sup>1</sup>, Luciano Riboldi<sup>4</sup>, Giovanna Rizzo<sup>1</sup>, Federica Rota<sup>1</sup>, Sabrina Sucato<sup>1</sup>, Letizia Tarantini<sup>1</sup>, Amedea Silvia Tirelli<sup>3</sup>, Luisella Vigna<sup>4</sup>, Pieralberto Bertazzi<sup>1,2</sup> and Angela Cecilia Pesatori<sup>1,2</sup>

## Abstract

**Background:** Despite epidemiological findings showing increased air pollution related cardiovascular diseases (CVD), the knowledge of the involved molecular mechanisms remains moderate or weak. Particulate matter (PM) produces a local strong inflammatory reaction in the pulmonary environment but there is no final evidence that PM physically enters and deposits in blood vessels. Extracellular vesicles (EVs) and their miRNA cargo might be the ideal candidate to mediate the effects of PM, since they could be potentially produced by the respiratory system, reach the systemic circulation and lead to the development of cardiovascular effects.

The SPHERE ("Susceptibility to Particle Health Effects, miRNAs and Exosomes") project was granted by ERC-2011-StG 282413, to examine possible molecular mechanisms underlying the effects of PM exposure in relation to health outcomes.

**Methods/design:** The study population will include 2000 overweight ( $25 < \text{BMI} < 30 \text{ kg/cm}^2$ ) or obese ( $\text{BMI} \geq 30 \text{ kg/cm}^2$ ) subjects presenting at the Center for Obesity and Work (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy).

Each subject donates blood, urine and hair samples. Extensive epidemiological and clinical data are collected. Exposure to PM is assigned to each subject using both daily  $\text{PM}_{10}$  concentration series from air quality monitors and pollutant levels estimated by the FARM (Flexible air Quality Regional Model) modelling system and elaborated by the Regional Environmental Protection Agency.

The recruitment period started in September 2010 and will continue until 2015. At December 31, 2013 we recruited 1250 subjects, of whom 87% lived in the province of Milan.

Primary study outcomes include cardiometabolic and respiratory health effects. The main molecular mechanism we are investigating focuses on EV-associated microRNAs.

(Continued on next page)

\* Correspondence: [valentina.bollati@unimi.it](mailto:valentina.bollati@unimi.it)

<sup>1</sup>Molecular Epidemiology and Environmental Epigenetics Laboratory, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Full list of author information is available at the end of the article

(Continued from previous page)

**Discussion:** SPHERE is the first large study aimed to explore EVs as a novel potential mechanism of how air pollution exposure acts in a highly susceptible population. The rigorous study design, the availability of banked biological samples and the potential to integrate epidemiological, clinical and molecular data will also furnish a powerful base for investigating different complementary molecular mechanisms. Our findings, if confirmed, could lead to the identification of potentially reversible alterations that might be considered as possible targets for new diagnostic and therapeutic interventions.

**Keywords:** Particulate matter, Obesity, Cardiovascular effects, Extracellular vesicles, Exosomes, Microvesicles, miRNAs

## Background

Air pollution is a major health concern which accounts for ~3.7 million global deaths annually, according to World Health Organization (WHO) estimates [1].

Numerous health studies have shown acute [2-7] and chronic [8-10] particulate air pollution exposures to be associated with early death, particularly from cardiovascular and respiratory diseases [3,10,11]. Metals, which are constituents of particulate air pollution, have been shown to be associated with cardiovascular diseases (CVD) as well [12-31]. Epidemiological and animal studies have suggested many potential mechanisms by which particles may impact health. Airway or parenchymal inflammatory responses to particulate matter (PM) have been hypothesized to be the inciting events of a cascade of pathophysiologic changes in autonomic cardiac, systemic inflammatory, and haemostatic activities. All these processes may ultimately lead to the acute events associated with PM exposure [32].

One of the most important gaps in our current knowledge regarding PM-related health effects is the identification of susceptible subjects [33]. Recent research findings pointed out obesity as a susceptibility factor to the adverse effects of PM exposure partly due to an increase in particle absorption [34]. A positive correlation between exhaled nitric oxide, a marker of pulmonary inflammation, and Body Mass Index (BMI) has been shown in healthy adults [35]. BMI was associated with a graded increase in the estimated total lung dose of deposited fine particles in an inhalation study of healthy children (6-13 years of age) [36]. In a panel study of 44 senior citizens, vascular inflammatory response (measured by C-reactive protein) to ambient levels of PM<sub>2.5</sub> (particulate matter with aerodynamic diameter  $\leq 2.5 \mu\text{m}$ ) averaged over 1-7 days was greater in obese (BMI  $\geq 30 \text{ kg/m}^2$ ) than in non-obese subjects [37]. Moreover, a differential autonomic cardiac response (measured as heart rate variability) to metal particulates has been observed between obese and non-obese individuals [33].

The mechanisms linking PM exposure and CVD have not yet been fully elucidated. It has been proposed that inhaled fine particulate matter translocates directly into the systemic circulation through the pulmonary capillary

bed, promoting atherothrombosis by breaching endothelial integrity and inciting a local inflammatory reaction [38]. However, just a very small fraction of these fine and ultrafine particles accumulate in extra pulmonary organs such as the liver and the spleen, [39] and currently there is no final evidence that fine particles physically enter and deposit in blood vessels. An alternative hypothesis is that ambient particles produce a strong inflammatory reaction in the lungs followed by the release of pro-inflammatory mediators that are able to reach the systemic circulation [40,41]. Despite more than two decades of mechanistic research, the recent statement of air pollution and cardiovascular disease from the American Heart Association remarked that compared to the high degree of consistency of the epidemiological findings showing increased cardiovascular risk, the evidence on intermediate mechanisms remains moderate or weak [42].

Beside the release of pro-inflammatory mediators, cell-derived membrane vesicles are also released, representing another way of intercellular communication that has recently become the subject of increasing interest [41]. Extracellular vesicles (EVs) are spherical structures limited by a lipid bilayer that can be generated by cells and secreted into the extracellular space and are likely composed of both exosomes (EXs) and microvesicles (MVs). The term exosome is used to identify a particular subgroup of vesicles, ranging from 40 to 100 nanometers (nm) in diameter, released as a consequence of multivesicular endosome (a membrane-bound intracellular vesicle, containing EXs) fusion with the plasma membrane, [43] whereas the term microvesicle is used for those EVs, larger than 100 nm in diameter, that are shed from the plasma membrane.

EVs are released from cell membranes as a consequence of triggers such as endotoxin encounter, hypoxia or oxidative stress conditions, cytokines release, thrombin production [44] and could be one of the means used by tissues to adapt to these stimuli [45]. EV membranes are enriched in specific surface molecules which could favor their capture by recipient cells. The fate of EVs, after binding the surface of recipient cells, is not known but recent evidences suggest that they might fuse and deliver their content directly into the cytoplasm. In addition,


after internalization in the target cells through surface-expressed ligands, EVs may transfer microRNAs (miRNAs) [46,47] allowing intercellular and inter-organ communication in the body [47]. MiRNAs are small, endogenous, single stranded noncoding RNAs of 20–22 nucleotides [48] that post-transcriptionally regulate gene expression by either triggering mRNA cleavage or repressing translation [49]. One single miRNA can regulate hundreds of mRNAs in interrelated gene pathways and a single mRNA can be targeted by several different miRNAs [50]. Moreover, miRNA expression in circulating EVs has been detected in plasma of normal subjects and a

predictive role of peripheral blood miRNA signatures in human diseases has also been hypothesized [47].

#### Aims and hypotheses

Taken together (Figure 1), these findings suggest that:

- Obese individuals might represent one of the best population to investigate the effects of environmental air particles on several molecular mechanisms and, as a final objective, on cardiovascular and respiratory parameters;



**Figure 1** Proposed mechanism for air pollution effects on microvesicle release and cell-to-cell communication.

- EVs might be the ideal candidate mechanism to mediate the effects of air pollution, since they could potentially be produced by the respiratory system, [51,52] reach the systemic circulation [53] and lead to the development of endothelial dysfunctions [54].

The specific aims of the first funded SPHERE grant (ERC-2011-StG 282413 to Valentina Bollati), are summarized in Figure 2 and reported below:

1. Determine whether exposure to air particles and PM-associated metals can modify EVs in plasma as quantity, size, characterization of the membrane molecules, procoagulant activity, miRNA content.
2. Determine whether the changes found in EVs are associated with CVD risk factors, such as aging, gender, smoking habits, alcohol consumption, BMI, blood pressure, medications, lipid metabolism, glucose homeostasis, homocysteine.
3. Determine whether the changes found in EVs predict alterations of CVD risk endpoints, such as inflammation markers (Cytokines), ECG (QRS, PR waves and heart rate), endothelial function (ICAM-1, VCAM-1, C-reactive protein), oxidative stress (8-hydroxy-2'-deoxyguanosine).

4. Determine whether exposure to air particles and PM-associated metals are associated with selected CVD risk factors (listed in aim 2).
5. Determine whether exposure to air particles and PM-associated metals predict alterations of CVD risk biomarkers (listed in 3).


We hereby present study design, field activities, management organization and characteristics of the enrolled subjects.

## Methods/design

### Study design

The SPHERE study is a cross-sectional study investigating the effects of particulate air pollution on a population of susceptible overweight/obese subjects, residing in Lombardy Region, Italy.

Lombardy is situated in the Northern part of Italy and is physically divided into three parts from north to south: Alpine and pre-Alpine mountains, foothills, and a zone of alluvial plains sloping to the Po river. The region covers an area of 23.864 km<sup>2</sup> with a population of about 10 million people [55] and consists of 12 provinces, among which Milan is the regional capital. The Milan metropolitan area counts 7 million inhabitants with 1.3 million residing in the core municipality [56].



**Figure 2** Conceptual model for the SPHERE study.

### Study subjects

The overall study enrollment target is to recruit 2,000 participants presenting at the Center for Obesity and Work, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. The recruitment period started in September 2010 and will continue until the end of 2015. At December 31, 2013 we recruited 1250 subjects, 87% of whom living in the province of Milan. The eligibility criteria for participants are: 1) older than 18 years at enrollment; 2) obese/overweight according to the following definition: overweight is defined as a BMI between 25 and 30 kg/cm<sup>2</sup>, obesity is defined as a BMI of 30 kg/cm<sup>2</sup> or more; 3) resident in Lombardy at the time of the recruitment; 4) agreement to sign an informed consent and donate blood and urine samples.

Exclusion criteria include: previous diagnosis of cancer, heart disease or stroke in the last year or other chronic diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, depression, bipolar disorder, schizophrenia and epilepsy [57]. The participation rate in the years 2010–2013 was 90%. The main characteristics of study participants are reported in Tables 1 and 2. Most participants are females (73.6%). The mean BMI is 33.5 Kg/cm<sup>2</sup> ( $\pm 5.5$ ): 27.8% are overweight, 38.6% obese, and 33.6% severe obese (BMI  $\geq 35$  Kg/cm<sup>2</sup>). The mean age is 51.9 years ( $\pm 13.6$ ).

### Epidemiological and clinical data collection

At recruitment, each study subject is asked to:

- fill in a lifestyle and a diet questionnaire,
- donate a 15 ml blood sample (for molecular tests),
- provide a 50 ml urine sample (for metal internal dose assessment),
- provide a lock of hair cut next to the root in the occipital area of the head (for metal internal dose assessment).

As part of the routine protocol, for each subject presenting at the Center, physical examination (including weight and height measured by a nurse following standardized procedures), spirometry, and electrocardiogram (ECG) are performed and biochemical parameters are also collected, including Emocrome, Fibrinogen, C-reactive protein, Total cholesterol, HDL, LDL, Triglyceride, Serum creatinine, AST, ALT, Gamma-Glutamyltransferase, fasting blood glucose, Homocysteine, TSH, Glycated haemoglobin, Post-prandial glycaemia, Insulin level, 2-hour post glucose insulin level, Urinary pH, Uric acid.

### Lifestyle questionnaire

The lifestyle questionnaire collects information on socio-demographic data, residential area (complete address, characteristics of the house, and traffic), education, smoking

history including passive smoking at home and at work-place, past and present health status of both the subjects and their first-degree relatives, medications in the last year, employment history and address of the plant of their current work (currently employed subjects only), physical activity levels and sedentary behavior, commuting time and transport mode.

### Diet questionnaire

The questionnaire on dietary habits includes questions on the number of servings from each food in a usual week or month. Several different types of food are investigated, including: legumes, vegetables, fruits, nuts, red and white meat, fish, eggs, dairy products, cereals, snacks, oil and butter, alcoholic beverage, tea and coffee. Number of servings from each food are translated into usual daily micronutrients intake weighting for serving size, age class and gender.

Both questionnaires are checked for completeness at the time of data collection in order to ensure high quality data.

### Lung and cardiac function

Pulmonary functions are measured, at the same day of blood drawing, with an electronic flow volume spirometer V-max 22 with Autobox (SensorMedics), according to European Respiratory Society/American Thoracic Society guidelines (ERS/ATS 2005) [58]. Tests are performed on patients in the sitting position, and are repeated until at least three reproducible forced expiratory curves have been obtained. Lung function parameters are: forced expiratory volume in one second (FEV<sub>1</sub>); forced vital capacity (FVC); best peak expiratory flow (PEF); forced expiratory flows at 25%, 50%, and 75% of FVC (FEF<sub>25</sub>, FEF<sub>50</sub>, FEF<sub>75</sub>); mid-expiratory flow (FEF<sub>25–75</sub>) derived from the best maneuver (defined as the one with the highest sum of FEV<sub>1</sub> + FVC). The single breath carbon monoxide diffusing capacity (DLCO) is also measured [59]. All parameters are expressed as a percentage of the predicted normal values, [60] and adjusted for sex, age, height.

A resting ECG and rhythm strip is also recorded and blood pressure is measured with the participant supine, after 5 minutes of rest.

### Biological sample collection

Specific laboratory Standard Operating Procedures have been developed to ensure quality control of every step involved in biospecimen collection and storage.

Blood is collected using two EDTA tubes (7 ml) and one PAX tube. Blood samples are transported from the Center for Obesity and Work to the Molecular Epidemiology and Environmental Epigenetics laboratory (University of Milan) within 2 hours from the phlebotomy. EDTA blood is processed to obtain whole blood, buffy coat, plasma, DNA, EV pellet. EDTA-blood is centrifuged



**Table 1 Demographic and lifestyle characteristics of study participants at 31/12/2013**

Characteristics	Categories	n = 1250
Sex	Male	330 (26.4%)
	Female	920 (73.6%)
Age	Years (mean ± SD)	51.9 ± 13.6
Education	Primary school or less	105 (8.4%)
	Secondary school	325 (26.0%)
	High school	493 (39.4%)
	University	188 (15.0%)
	Others	87 (7.0%)
Occupation	Missing	52 (4.2%)
	Employee	714 (57.1%)
	Unemployed	102 (8.2%)
	Pensioner	304 (24.3%)
Ethnicity	Housewife	93 (7.4%)
	Missing	37 (3.0%)
	White	1198(95.8%)
	Black	11 (0.9%)
Year of enrollment	Asian	3 (0.3%)
	South America	38 (3.0%)
	2010	129 (10.3%)
	2011	419 (33.5%)
Season of enrollment	2012	385 (30.8%)
	2013	317 (25.4%)
	Winter	320 (25.6%)
	Spring	313 (25.0%)
Smoking	Summer	190 (15.2%)
	Autumn	427 (34.2%)
	Never	599 (47.9%)
	Former	431 (34.5%)
Cigarettes smoked* [cigarettes/day]	Current	190 (15.2%)
	Missing	30 (2.4%)
	<= 5	53 (27.9%)
	5-10	53 (27.9%)
	10-15	33 (17.4%)
	15-20	37 (19.6%)
Time since quitting (n = 419)	20-40	13 (6.8%)
	Missing	1 (0.5%)
Pack/years (n = 1153)	Median [Q1, Q3]	13.1 [5.8–23.4]
Among current and former smokers		14.5 [6.1–28.0]
Including nonsmokers		0 [0–13.5]

**Table 1 Demographic and lifestyle characteristics of study participants at 31/12/2013 (Continued)**

Alcohol consumption	Yes	636 (50.9%)
	No	518 (41.4%)
	Missing	96 (7.7%)
Residence area	City	534 (42.7%)
	Peripheral area	331 (26.5%)
	Rural area	30 (2.4%)
	Village/small city	206 (16.5%)
	Missing	149 (11.9%)
Living area	Province of Milan (Excluding City of Milan)	379 (30.3%)
	City of Milan	713 (57.0%)
	Outside Milan	158 (12.7%)
Work area	Province of Milan (Excluding City of Milan)	94 (13.1%)
	City of Milan	339 (47.5%)
	Outside Milan	34 (4.8%)
Floor of residence	Missing	247 (34.6%)
	Ground floor	223 (17.8%)
	First floor	244 (19.5%)
	Second floor	156 (12.5%)
Residence traffic exposure	Beyond second floor	471 (37.7%)
	Missing	156 (12.5%)
	Mild	108 (8.7%)
	Moderate	595 (47.6%)
	Heavy	369 (29.5%)
	Missing	178 (14.2%)

\*Among current smokers; Q1: first quartile; Q3: third quartile.

1,100 × g for 15 minutes at room temperature to obtain platelet-free blood plasma and buffy coat. An aliquot of plasma is further centrifuged at 1,000, 2,000, and 3,000 × g for 15 minutes at 4°C to remove cell debris. To prepare EV pellet, 1.5 mL of fresh plasma is transferred into a ultracentrifuge tube (Quick-Seal®- Round-Top, Polypropylene, 13.5 mL-Beckman Coulter, Inc) and filled up with PBS, filtered with 0.10 µm pore size membrane (StericupR-VP, 0.10 µm, polyethersulfone filter- Merck Millipore) to minimize the background contribution of interfering particles.

PAX tubes are used for RNA collection and extraction since they contain a solution that inhibits RNA degradation and gene induction as blood is drawn into the tube.

A 50 ml urine sample is also collected and frozen at -20°C.

A lock of hair is cut next to the root in the occipital area of the head. A segment of 3 cm length is then washed to remove external contaminations and dissolved in alkaline solvent.

**Table 2 Main clinical characteristics of the study subjects at December 31, 2013**

Characteristics	N	
BMI, Kg/cm <sup>2</sup>	1247	33.5 ± 5.5
BMI categorical		
<30 Kg/cm <sup>2</sup>		347 (27.8%)
30-35 Kg/cm <sup>2</sup>		483 (38.6%)
≥35 Kg/cm <sup>2</sup>		420 (33.6%)
Waist circumference, cm	1237	101.3 ± 13.1
Blood pressure, mmHg	1247	
Sistolic		125.4 ± 15.8
Diastolic		78.5 ± 9.5
Above 140/90 mmHg		60 (4.8%)
Below 140/90 mmHg		1190 (95.2%)
Heart rate, bpm	1243	67.6 ± 10.4
Uric acid	1163	5.2 ± 1.4
Fibrinogen, mg/dl	1129	335 ± 59
C-reactive protein	1160	0.3 [0.1-0.5]
Total cholesterol, mg/dl	1165	215.1 ± 41
HDL		59.2 ± 15.5
LDL		134.7 ± 36.3
Triglyceride	1164	107 [77-145.5]
Serum creatinine, mg/dL	1165	0.8 ± 0.3
AST, U/l	1159	19 [16-23]
ALT, U/l	1160	21 [16-30.5]
Gamma-Glutamyltransferase, IU/L	1162	19 [13-30]
Glucose	1155	92 [86-101]
Homocysteine	1151	10.4 [8.6-12.7]
TSH	1163	1.7 [1.2-2.5]
Glycated hemoglobin, mmol/mol	1159	39 [36.6-43]
Postprandial glycaemia, mg/dl	1162	99 [90-112]
Insulin level	1158	12.3 [8.8-18]
2-hour post glucose insulin level	1155	46.4 [27.6-73]
Urinary pH	1144	5.6 ± 0.7
Emocrome	1156	
White blood cells		6.8 ± 1.7
Red blood cells		4.8 ± 0.4
Hemoglobin		13.8 ± 1.4
Hematocrit		40.7 ± 3.4
Mean Corpuscular Volume		85.1 ± 6.4
Platelets		249.7 ± 59

Continuous variable are expressed as mean ± standard deviation (SD) or as median [first quartile-third quartile] if not normally distributed; discrete variables are expressed as counts (%).

Biospecimens are tracked through a secure database that stores detailed information on sample description, aliquoting and freezer locations.

Approximately 90% of study subjects donated a blood sample, 99% donated a urine sample and 57% donated a lock of hair.

#### Extracellular vesicles and miRNA investigation

In the SPHERE project, we apply a novel methodology aimed at investigating EVs in human plasma. This comprehensive approach, involves the characterization of microvesicular membrane determinants (to assess their cellular origin) by Flow Cytometry, microvesicle size and count by Nanosight (nanoparticle tracking analysis, NTA), and evaluation of microvesicle content (miRNAs).

For miRNA analysis, we follow a two-stage, split sample study design. The first (discovery) stage involves genome-wide miRNA expression profiling among 1,000 participants (the first 1,000 subjects consecutively recruited). The second (validation) stage involves a replication analysis of the top 50 miRNAs that resulted from the first stage. In particular, Stage 1 will involve the use of OpenArray technology (Applied Bioscience) that allows to run 2,688 TaqMan® qPCR reactions in parallel. In Stage 2, we will replicate the results obtained on the discovery set by standard real time PCR on an Applied Biosystems 7900HT Real-Time PCR System. Given the nature of this study and the lack of prior information on the investigated association, a formal power calculation was not possible. A simulation study showed that a sample size of 1000 subjects allows to obtain a power of 98% to detect a modest effect (at least 0.1 SD change) on miRNAs expression, for a 1 SD change in exposure.

#### Exposure assessment

Exposure is defined using a multifaceted approach, which integrates information on particulate air pollution exposure with personal dose of metals in urine and hair. In particular, PM<sub>10</sub> is assigned to each subjects following two approaches: (1) daily PM<sub>10</sub> concentration series from air quality monitors; (2) daily PM<sub>10</sub> concentrations estimated with the FARM (Flexible Air quality Regional Model) model, a three-dimensional Eulerian grid model for dispersion, transformation and deposition of particulates, capable to simulate PM<sub>10</sub> concentration using a 4 km-dispersion grid [7].

In addition, we will perform personal air pollution measures of PM (including also PM<sub>2.5</sub>), using passive samplers, on a subgroup of selected subjects (n = 200).

#### Air monitoring stations

We obtained from the Regional Environmental Protection Agency (ARPA Lombardia) recordings of daily air levels of PM<sub>10</sub> measured from monitoring stations located at 154 different sites throughout Lombardy since 2001. Three of them are located in the city of Milan ("Verziere", "Pascal-Città Studi" and "Senato"). Nitrogen

dioxide (NO<sub>2</sub>), carbon monoxide (CO) and ozone (O<sub>3</sub>) measurements were also available. We used daily concentrations measured by single monitors in the study area to characterize PM<sub>10</sub> exposure at the date of recruitment and back to 365 days before enrollment, for each subject. Thus, we were able to evaluate both short- and long-term exposure to the investigated pollutant.

We geocoded the addresses of monitoring stations and study subjects in order to assign to each subject the daily PM<sub>10</sub> concentration from: (1) the nearest monitor to home address, defined as “subjects’ residence”; (2) the nearest monitor to the Center for Obesity and Work (defined as “Policlinico”); (3) the Milan mean daily exposure (averaging the three available city monitors), defined as “average Milan”.

In case of incomplete series, each missing value was imputed by using an algorithm that integrates the annual average of the incomplete series and PM<sub>10</sub> concentrations of the nearest and more correlated monitors [61].

About 57% of SPHERE subjects lives in Milan and an additional 28% works in the city (even if they lived outside the city); overall 67% of subjects spent many hours a day in the city or travelling from workplace to residence.


We considered subject PM<sub>10</sub> levels measured at the “Policlinico” station as representative of mean PM<sub>10</sub> concentrations during the day of enrollment. Moreover, very high correlation was observed among the three sources of exposure ( $R_{\text{Policlinico vs Average Milan}} = 0.99$ ;  $R_{\text{Subjects' Residence vs Average Milan}} = 0.94$ ;  $R_{\text{Policlinico vs Subjects' Residence}} = 0.99$ ). We also calculated different lag time exposure windows from recruitment date using residential and Milan monitors.

To give a map representation of PM<sub>10</sub> from monitoring stations, we applied a geostatistical interpolated method (Empirical Bayesian kriging) that expands the monitor PM<sub>10</sub> point observations to the whole Lombardy territory (Figure 3A) [62].

#### FARM model

Estimated daily average concentrations of PM<sub>10</sub> for the years 2007–2012 based on the FARM model were obtained from ARPA Lombardy. The FARM model is a chemical transport model able to treat the main processes of chemical and physical nature involved in the formation and removal of pollutants, in addition to their transport and dispersion due to the action of wind and atmospheric mixing. The imputed data are built from meteorological observations of weather and hydrological network of ARPA and from processing of the results of the global meteorological model of the ECMWF (European Centre for Medium-Range Weather Forecasts). The initial and boundary conditions are obtained from the ARPA network data and the results of the model CHIMERE (<http://www.lmd.polytechnique.fr/chimere/chimere.php>). Finally, data on measured and simulated concentrations are harmonized through interpolation techniques [7,63,64]. By this model the Lombardy region is divided into a grid of 1678 cells (4×4 km), each associated with daily PM<sub>10</sub> concentration estimates.

Hence, each subject was attributed the estimated mean daily exposure of: (1) the cell containing the residential address; (2) the cell containing the address of the Center for Obesity and Work; (3) the city of Milan, calculated



**Figure 3** Graphical representation of PM<sub>10</sub> concentration levels. **A:** Point measurements from monitoring stations expanded to the whole Lombardy territory through Empirical Bayesian Kriging (2010–2013). **B:** PM<sub>10</sub> concentrations predicted by FARM model (2010–2012).



as the average of the 22 cells that fall into the city boundaries.

Data estimated from the models are currently available until 2012, since the data validation imply a lag time of nearly 6 months, and will soon be available for further data analysis. A map of predicted PM<sub>10</sub> concentrations (2010–2012) is shown in Figure 3B.

Both air quality measuring and modeling have some degree of uncertainty. Monitoring station measurements are often hampered by low spatial resolution (point data). On the other hand, modelling techniques have inherent constraints, due to the limited ability to perfectly describe physical phenomena and the intrinsic variability of the imputed data [65].

The distribution of daily mean PM<sub>10</sub> concentrations (2010–2012) derived from both the monitoring stations and the FARM model is reported in Figure 4. PM<sub>10</sub> estimates have, on average, lower values than measured concentrations (see also Additional file 1: Figure S1). During winter months (October to February) this difference is more evident (see also Additional file 2: Table S1).

FARM model performance was examined using a standard performance metric: the Mean Fractional Bias (MFB), which is a measure of the model tendency to over- or under-predict the observations from monitors. The MFB is defined as the normalized average difference between all model-observed pairs and can vary between  $\pm 200\%$ . The model performance goal is met when the MFB is between  $\pm 30\%$  [65,66]. We obtained MFB =  $-16\%$  for the entire period of comparison and year specific MFBs remained within the range. These results suggest the fulfillment of the objective of performance, confirm the tendency to underestimate the measured concentrations, and


are consistent with the ARPA Lombardy Annual Assessment Of Air Quality Modeling for years 2009–2011 [64].

According to the Italian Legislative Decree 13 August, 2010, nr. 155 (Annex I), implementing the European Union Directive 2008/50/EC, ratios between measured and estimated data must be between  $\pm 50\%$  in order to consider the data quality as acceptable [64,67]. Our calculated ratios all fell in the data quality range, except for three monitors not linked to any subjects' residence (see Additional file 1: Figure S2). Analyses performed for each year and over the entire time period gave comparable results.

In interpreting the above listed exposure assessment findings, it is important to consider that measurements from monitoring stations should not necessarily be considered as the gold-standard. The differences between the measured and estimated air pollutant levels may be partially explained by the fact that a point measurement is compared to a mean concentration modeled in volumetric grid cell. The former unlikely represents the average concentration over the same volume of air, making it difficult to obtain a perfect match between the two methods. The ability of the model to deeply take into account meteorological variables could also play an important role [65].

#### Internal dose of metals/elements

As part of the routine protocol, for each subject presenting at the center a 50 ml urine sample and a hair sample are collected, in order to quantify metals in urine and hair. Urine gives short term information (few hours before sample collection). Hair is also regarded as a valuable matrix as during its growth (about 1 cm per month)



**Figure 4** Estimated and observed daily mean PM<sub>10</sub> concentrations (2010–2012). Daily mean PM<sub>10</sub> concentrations of all monitors and of all grid cells with a monitor falling into their boundary. Darker area highlights winter months, characterized by major differences between the two methods of exposure assessment.

it accumulates toxic substances. We analyze a lock of hair (a 3 cm-length segment), cut next to the root in the occipital area of the head, roughly corresponding to 3 months of exposure. The parallel quantification of metals in urine and hair gives complementary data on medium- and short-term exposure. Trace metals/elements measured by ICP/MS include: Aluminum, Antimony, Arsenic, Beryllium, Bismuth, Cadmium, Lead, Mercury, Platinum, Thallium, Uranium, Nickel, Silver, Titanium, Calcium, Magnesium, Sodium, Potassium, Copper, Zinc, Manganese, Chromium, Vanadium, Molybdenum, Boron, Iodine, Lithium, Phosphorus, Selenium, Strontium, Sulfur, Barium, Cobalt, Iron, Germanium, Rubidium, Zirconium.

### **Ethical issues**

The study design, research aims and measurements have been approved by the local Institutional Review Board ('Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico' review board).

Each participant was asked to sign a written informed consent explaining the study in detail. New measurements will only be embedded in the study after approval of the Ethical Committee.

### **Data management and privacy protection**

A study collecting a large amount of information which are updated daily, such as SPHERE, requires highly efficient data management systems.

In order to protect the privacy of each subject, all information and biological samples collected from the subject are anonymized of personally identifying information and will be identified only through a 5-digit randomly assigned barcode. The link between the barcode and the subject's identity is held in a secure database.

All questionnaire data collected through paper forms, are imputed in the database and quality and completeness control are performed weekly. All data are combined in a central relational database (MS SQL Server).

Data processing is anonymous and the highest level of confidentiality is maintained for all identifying information. We routinely check quality of collected data by comparing information from different sources (e.g. questionnaires, clinical records, biochemical exams); assessing variable range and distribution; evaluating the quality of biospecimens through specific analyses conducted on random samples; and verifying the database completeness through multiple queries.

A complete list of all collected variables is reported in Additional file 2: Table S2.

### **Dissemination of results**

A project's website is being implemented and will be updated regularly (<http://users.unimi.it/sphere>). It will contain complete information about the project and relevant

events. All publishable material and reports will be put online as they are produced. The results from the project will be converted into user-friendly protocols and published in press releases, educational programs, conferences, and scientific journals.

### **Opportunities to collaborate**

We designed SPHERE being aware that much of its value would arise from involvement with other investigators, individually and within consortia. The SPHERE project is open for collaboration with interested investigators. Given the detailed epidemiological data available, such as the clinical information collected, and the molecular data, SPHERE will provide a good environment for collaborations. Proposals from outside the study team for research projects to test specific hypotheses on SPHERE population will be reviewed by our research team. Requests can be sent to the e-mail [sphere@unimi.it](mailto:sphere@unimi.it).

### **Discussion**

The investigation of mechanisms linking air pollutant inhalation to cardiovascular effects is being considered a pressing priority [40,68].

The SPHERE study is, at the best of our knowledge, the first study primarily designed to determine whether exposure to air particles and PM-associated metals can modify EVs (as quantity, size, membrane molecules, procoagulant activity and miRNA content) in plasma of human subjects and to investigate whether these alterations may be linked to cardiovascular risk factors and outcomes.

The identification of miRNAs in plasma EVs of healthy subjects [47] provides the basis for a new potential mechanism, since EVs produced by lung or dendritic cells might be able to transfer a specific pattern of miRNAs to immune and endothelial cells.

We will be able to examine the above mentioned mechanism in a large group of human subjects particularly susceptible to the effects of air pollution, measuring EV production and content (miRNAs) in plasma. For this purpose, we developed a novel methodology which involves the characterization of microvesicular membrane determinants (to assess their cellular origin) by Flow cytometry, microvesicle sizing and counting by Nanosight technology, and microvesicle content (miRNAs) analysis by highly quantitative OpenArray technology (Quant Studio, Applied Bioscience). Openarray technique will allow to analyze, in an unbiased way, the entire miRNome in one single reaction and will produce very precise and accurate data. Moreover, the inclusion in the study protocol of a discovery stage (1000 samples) followed by a confirmation stage (1000 samples), will lower the possibility to find false positive results.

Thus, if we were successful in identifying miRNA alterations in EVs, we could detect the opportunity of

using an easily obtainable biological media (plasma) for potential future preventive and diagnostic applications. In addition, as miRNAs in EVs may be a possible drug target, our study might also open paths to develop future interventions to reverse the effects of air pollution.

The extensive clinical and biochemical data collected for each subject will help in examining the relationships under study taking into account the possible role of other covariates.

The characterization of subjects' exposures can rely on various sources of exposure assessment: monitoring stations, personal samplers, model estimates, and internal dose measurements.

The availability of PM measurements from past years and the use of diverse lag-time windows will allow to investigate both long- and short-term exposure effects. Residential, workplace and mobility information collected through questionnaires will improve the accuracy of subject-specific exposure assessment.

A further validation of the exposure indexes will be provided by the use of passive samplers in a subgroup of subjects. We will also integrate all the information with urine and hair metal measurements.

Finally, the huge amount of available data will offer the opportunity to implement further new modelling techniques as long as they might come out.

In conclusion, SPHERE is the first large study aimed to explore EVs as a novel potential mechanism of action of air pollution exposure in a highly susceptible population. The rigorous study design, the availability of banked biological samples and the potential to integrate epidemiological, clinical and molecular data will also furnish a powerful base for investigating different complementary molecular mechanisms.

## Additional files

**Additional file 1: Figure S1.** Estimated and observed mean PM<sub>10</sub> level by place. **Figure S2.** Data quality control on FARM model estimates (2010–2012) according to EU Directive 2008/50/EC. Each point represents PM<sub>10</sub> mean concentrations as measured by monitoring stations (x axis) and estimated by FARM model in the corresponding cells (y axis). The cone dotted lines delimit the  $\pm 50\%$  range of data quality.

**Additional file 2: Table S1** PM<sub>10</sub> profile (overall and by season) and selected weather variables (2010–2012). All values are calculated at the time of blood sampling. **Table S2.** Complete list of variables collected for the SPHERE study.

## Abbreviations

BMI: Body Mass Index; CTM: Chemical Transport Models; ECG: Electrocardiogram; EVs: Extracellular vesicles; FEF<sub>25</sub>: Forced expiratory flows at 25%; FEF<sub>50</sub>: Forced expiratory flows at 50%; FEF<sub>75</sub>: Forced expiratory flows at 75%; FEV<sub>1</sub>: Forced expiratory volume in one second; FVC: Forced vital capacity; miRNAs: microRNAs; PEF: Peak expiratory flow; PM: Particulate Matter.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

VB and ACP had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; VB designed and supervised the molecular study; ACP designed and supervised the epidemiological implant of the study; RC and BM contributed to patients recruitment and database preparation; BA, BDG, TC, LD, GR, FR, LT undertook the lab procedures; LC, MH, LP performed EV analysis; LD and VM performed miRNA analysis; SF and SS performed quantification of metals in urine and hair; LP, LR, AST and LV were responsible for blood clinical analysis and clinical outcome measurements; SI, CF, VB, ACP, and PAB drafted and revised the manuscript; SI, CF, LA statistically analyzed the data; SI, CF, LA and MC contributed in PM exposure assessment; VB obtained fundings. All authors read and approved the final manuscript.

## Acknowledgements

This study was supported by the EU Programme "Ideas" (ERC-2011-StG 282413, to VB).

We thank the Occupational Medicine Medical Residents for their help in examining and recruiting the study subjects. We are grateful to the nurses of the "Medicina del Lavoro" Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, the nutritionist Daniela Sommaruga, the Scientific Director of "Osservatorio Grana Padano" Maria Letizia Petroni, Enrico Radice for database development, Elisabetta Angiolino from Regional Environmental Protection Agency (ARPA), as well as the volunteers who participated in the study.

## Author details

<sup>1</sup>Molecular Epidemiology and Environmental Epigenetics Laboratory, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. <sup>2</sup>Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. <sup>3</sup>Laboratory of Clinical Chemistry & Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. <sup>4</sup>Worker's Health Protection and Promotion Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Received: 2 October 2014 Accepted: 15 October 2014

Published: 4 November 2014

## References

1. World Health Organization: **Burden of disease from Ambient Air Pollution for 2012 - Summary of Results.** In Geneva, Switzerland: WHO; 2014.
2. Schwartz J, Marcus A: **Mortality and air pollution in London: a time series analysis.** *Am J Epidemiol* 1990, **131**(1):185–194.
3. Schwartz J, Dockery DW: **Increased mortality in Philadelphia associated with daily air pollution concentrations.** *Am Rev Respir Dis* 1992, **145**(3):600–604.
4. Katsouyanni K, Touloumi G, Spix C, Schwartz J, Balducci F, Medina S, Rossi G, Wojtyniak B, Sunyer J, Bacharova L, Schouten JP, Ponka A, Anderson HR: **Short-term effects of ambient sulphur dioxide and particulate matter on mortality in 12 European cities: results from time series data from the APHEA project.** *Air Pollution and Health: a European Approach.* *Bmj* 1997, **314**(7095):1658–1663.
5. Katsouyanni K, Touloumi G, Samoli E, Gryparis A, Le Tertre A, Monopoli Y, Rossi G, Zmirou D, Ballester F, Boumghar A, Anderson HR, Wojtyniak B, Paldy A, Braunstein R, Pekkanen J, Schindler C, Schwartz J: **Confounding and effect modification in the short-term effects of ambient particles on total mortality: results from 29 European cities within the APHEA2 project.** *Epidemiology* 2001, **12**(5):521–531.
6. Kinney PL, Ozkaynak H: **Associations of daily mortality and air pollution in Los Angeles County.** *Environ Res* 1991, **54**(2):99–120.
7. Silibello C, Calori G, Brusasca G, Giudici A, Angelino E, Fossati G, Peroni E, Buganza E: **Modelling of PM10 concentrations over Milano urban area using two aerosol modules.** *Environ Model Software* 2008, **23**(3):333–343.
8. Dockery DW, Pope CA 3rd, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG Jr, Speizer FE: **An association between air pollution and mortality in six U.S. cities.** *N Engl J Med* 1993, **329**(24):1753–1759.
9. Pope CA 3rd, Thun MJ, Namboodiri MM, Dockery DW, Evans JS, Speizer FE, Heath CW Jr: **Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults.** *Am J Respir Crit Care Med* 1995, **151**(3 Pt 1):669–674.

10. Pope CA 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, Godleski JJ: **Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease.** *Circulation* 2004, **109**(1):71–77.
11. EPA: **Integrated Science Assessment for Particulate Matter.** In *Research Triangle Part.* NC: U.S. Environmental Protection Agency; 2009.
12. Yeh S, How SW: **A pathological study on the blackfoot disease in Taiwan.** *Rep Inst Pathol Natl Taiwan Univ* 1967, **14**:25–73.
13. Tseng WP: **Effects and dose–response relationships of skin cancer and blackfoot disease with arsenic.** *Environ Health Perspect* 1977, **19**:109–119.
14. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY: **Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease.** *Arteriosclerosis* 1988, **8**(5):452–460.
15. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY: **Dose–response relationship between ischemic heart disease mortality and long-term arsenic exposure.** *Arterioscler Thromb Vasc Biol* 1996, **16**(4):504–510.
16. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL, Tai TY: **Increased prevalence of hypertension and long-term arsenic exposure.** *Hypertension* 1995, **25**(1):53–60.
17. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ: **Dose–response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic.** *Stroke* 1997, **28**(9):1717–1723.
18. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ: **Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan.** *Environ Health Perspect* 2000, **108**(9):847–851.
19. Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, Chiou HY, Wu MM, Chen CJ: **Biological gradient between long-term arsenic exposure and carotid atherosclerosis.** *Circulation* 2002, **105**(15):1804–1809.
20. Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, Guallar E: **Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence.** *Am J Epidemiol* 2005, **162**(11):1037–1049.
21. Carroll RE: **The relationship of cadmium in the air to cardiovascular disease death rates.** *Jama* 1966, **198**(3):267–269.
22. Voors AW, Shuman MS: **Liver cadmium levels in North Carolina residents who died of heart disease.** *Bull Environ Contam Toxicol* 1977, **17**(6):692–696.
23. Voors AW, Shuman MS, Johnson WD: **Additive statistical effects of cadmium and lead on heart-related disease in a North Carolina autopsy series.** *Arch Environ Health* 1982, **37**(2):98–102.
24. Elliott P, Arnold R, Cockings S, Eaton N, Jarup L, Jones J, Quinn M, Rosato M, Thornton I, Toledano M, Tristan E, Wakefield J: **Risk of mortality, cancer incidence, and stroke in a population potentially exposed to cadmium.** *Occup Environ Med* 2000, **57**(2):94–97.
25. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E: **Lead, cadmium, smoking, and increased risk of peripheral arterial disease.** *Circulation* 2004, **109**(25):3196–3201.
26. Jeong EM, Moon CH, Kim CS, Lee SH, Baik EJ, Moon CK, Jung YS: **Cadmium stimulates the expression of ICAM-1 via NF-kappaB activation in cerebrovascular endothelial cells.** *Biochem Biophys Res Commun* 2004, **320**(3):887–892.
27. Schwartz J: **Lead, blood pressure, and cardiovascular disease in men.** *Arch Environ Health* 1995, **50**(1):31–37.
28. Moller L, Kristensen TS: **Blood lead as a cardiovascular risk factor.** *Am J Epidemiol* 1992, **136**(9):1091–1100.
29. Gerhardsson L, Hagmar L, Rylander L, Skerfving S: **Mortality and cancer incidence among secondary lead smelter workers.** *Occup Environ Med* 1995, **52**(10):667–672.
30. Lustberg M, Silbergeld E: **Blood lead levels and mortality.** *Arch Intern Med* 2002, **162**(21):2443–2449.
31. Schafer JH, Glass TA, Bressler J, Todd AC, Schwartz BS: **Blood lead is a predictor of homocysteine levels in a population-based study of older adults.** *Environ Health Perspect* 2005, **113**(1):31–35.
32. Lippmann M, Frampton M, Schwartz J, Dockery D, Schlesinger R, Koutrakis P, Froines J, Nel A, Finkelstein J, Godleski J, Kaufman J, Koenig J, Larson T, Luchtel D, Liu LJ, Oberdorster G, Peters A, Sarnat J, Sioutas C, Suh H, Sullivan J, Utell M, Wichmann E, Zeilikoff J: **The U.S. environmental protection agency particulate matter health effects research centers program: a midcourse report of status, progress, and plans.** *Environ Health Perspect* 2003, **111**(8):1074–1092.
33. Chen JC, Cavallari JM, Stone PH, Christiani DC: **Obesity is a modifier of autonomic cardiac responses to fine metal particulates.** *Environ Health Perspect* 2007, **115**(7):1002–1006.
34. Adam M, Schikowski T, Carsin AE, Cai Y, Jacquemin B, Sanchez M, Vierkotter A, Marcon A, Keidel D, Sugiri D, Al Kanani Z, Nadif R, Siroux V, Hardy R, Kuh D, Rochat T, Bridevaux PO, Eeftens M, Tsai MY, Villani S, Phuleria HC, Birk M, Cyrus J, Cirach M, de Nazelle A, Nieuwenhuijsen MJ, Forsberg B, de Hoogh K, Declercq C, Bono R, et al: **Adult lung function and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis.** *The European respiratory journal* 2014, [Epub ahead of print].
35. De Winter-de Groot KM, Van der Ent CK, Prins I, Tersmette JM, Uiterwaal CS: **Exhaled nitric oxide: the missing link between asthma and obesity?** *J Allergy Clin Immunol* 2005, **115**(2):419–420.
36. Bennett WD, Zeman KL: **Effect of body size on breathing pattern and fine-particle deposition in children.** *J Appl Physiol* 2004, **97**(3):821–826.
37. Dubowsky SD, Suh H, Schwartz J, Coull BA, Gold DR: **Diabetes, obesity, and hypertension may enhance associations between air pollution and markers of systemic inflammation.** *Environ Health Perspect* 2006, **114**(7):992–998.
38. Nemmar A, Vanbilloen H, Hoylaerts MF, Hoet PH, Verbruggen A, Nemery B: **Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster.** *Am J Respir Crit Care Med* 2001, **164**(9):1665–1668.
39. Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, de la Fuente JM, Cassee FR, Boon NA, Macnee W, Millar AM, Donaldson K, Newby DE: **Do inhaled carbon nanoparticles translocate directly into the circulation in humans?** *Am J Respir Crit Care Med* 2006, **173**(4):426–431.
40. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M, Samet J, Smith SC Jr, Tager I, Expert Panel on Population and Prevention Science of the American Heart Association: **Air pollution and cardiovascular disease: a statement for healthcare professionals from the expert panel on population and prevention science of the American heart association.** *Circulation* 2004, **109**(21):2655–2671.
41. Al-Nedawi K, Meehan B, Rak J: **Microvesicles: messengers and mediators of tumor progression.** *Cell Cycle* 2009, **8**(13):2014–2018.
42. Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitsel L, Kaufman JD, American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism: **Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American heart association.** *Circulation* 2010, **121**(21):2331–2378.
43. Raposo G, Stoorvogel W: **Extracellular vesicles: exosomes, microvesicles, and friends.** *J Cell Biol* 2013, **200**(4):373–383.
44. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R: **Microparticles in cardiovascular diseases.** *Cardiovasc Res* 2003, **59**(2):277–287.
45. Thery C, Ostrowski M, Segura E: **Membrane vesicles as conveyors of immune responses.** *Nat Rev Immunol* 2009, **9**(8):581–593.
46. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO: **Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.** *Nat Cell Biol* 2008, **10**(12):1470–1476.
47. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB: **Detection of microRNA expression in human peripheral blood microvesicles.** *PLoS One* 2008, **3**(11):e3694.
48. Baccarelli A, Bollati V: **Epigenetics and environmental chemicals.** *Current Opinion in Pediatrics* 2009, **21**(2):243–251. 210.1097/MOP.1090b1013c.32832925cc.
49. He L, Hannon GJ: **MicroRNAs: small RNAs with a big role in gene regulation.** *Nat Rev Genet* 2004, **5**(7):522–531.
50. Lewis BP, Burge CB, Bartel DP: **Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.** *Cell* 2005, **120**(1):15–20.
51. Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O'Neal W, Pickles RJ, Sheehan JK: **Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense.** *FASEB J* 2009, **23**(6):1858–1868.



52. Prado N, Marazuela EG, Segura E, Fernandez-Garcia H, Villalba M, Thery C, Rodriguez R, Batanero E: **Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction.** *J Immunol* 2008, **181**(2):1519–1525.
53. Orozco AF, Lewis DE: **Flow cytometric analysis of circulating microparticles in plasma.** *Cytometry A* 2010, **77**(6):502–514.
54. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A: **The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases.** *Can J Cardiol* 2010, **26**(4):140–145.
55. **Regional statistical yearbook.** [http://www.asr-lombardia.it/]
56. **Comune di Milano - settore statistica.** [http://allegati.comune.milano.it/Statistica/Popolazione/Popolazione%202013/cleta\_zone\_eta\_2013.pdf]
57. **ISTAT: Multipurpose Survey of Households "Aspects of Daily Life".** [http://noi-italia2014.istat.it/fileadmin/user\_upload/allegati/S06I09M02pb\_2013.xls]
58. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: **Standardisation of spirometry.** *Eur Respir J* 2005, **26**(2):319–338.
59. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J: **Standardisation of the single-breath determination of carbon monoxide uptake in the lung.** *Eur Respir J* 2005, **26**(4):720–735.
60. European Respiratory Society: **Standardized lung function testing. Official statement of the European Respiratory Society.** *Eur Respir J Suppl* 1993, **16**:1–100.
61. Biggeri A, Baccini M, Bellini P, Terracini B: **Meta-analysis of the Italian studies of short-term effects of air pollution (MISA), 1990–1999.** *Int J Occup Environ Health* 2005, **11**(1):107–122.
62. Vicedo-Cabrera AM, Biggeri A, Grisotto L, Barbone F, Catelan D: **A Bayesian kriging model for estimating residential exposure to air pollution of children living in a high-risk area in Italy.** *Geospat Health* 2013, **8**(1):87–95.
63. Gariazzo C, Silibello C, Finardi S, Radice P, Piersanti A, Calori G, Cecinato A, Perrino C, Nussio F, Cagnoli M, Pelliccioni A, Gobbi GP, Di Filippo P: **A gas/aerosol air pollutants study over the urban area of Rome using a comprehensive chemical transport model.** *Atmos Environ* 2007, **41**(34):7286–7303.
64. **Regional Environmental Protection Agency (ARPA Lombardy).** [http://www2.arpalombardia.it/qariafiles/varie/Report\_VMQA2011.pdf]
65. Boylan CR, Russell GE: **PM and light extinction model performance metrics, goals, and criteria for three-dimensional air quality models.** *Atmos Environ* 2006, **40**:4946–4959.
66. Thunis PEG, Pederzoli A: **The DELTA tool and Benchmarking Report template Concepts and User's Guide.** In *Joint Research Centre, Ispra*. 2011. [http://fairmode.jrc.ec.europa.eu/document/fairmode/WG1/FAIRMODE\\_SG4\\_Report\\_April2011.pdf](http://fairmode.jrc.ec.europa.eu/document/fairmode/WG1/FAIRMODE_SG4_Report_April2011.pdf).
67. Hirsch EC, Vyas S, Hunot S: **Neuroinflammation in Parkinson's disease.** *Parkinsonism Relat Disord* 2012, **18**(Suppl 1):S210–212.
68. Brook RD: **Air pollution: what is bad for the arteries might be bad for the veins.** *Arch Intern Med* 2008, **168**(9):909–911.

doi:10.1186/1471-2458-14-1137

**Cite this article as:** Bollati *et al.*: Susceptibility to particle health effects, miRNA and exosomes: rationale and study protocol of the SPHERE study. *BMC Public Health* 2014 **14**:1137.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

